What happened with LXRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Lexicon Pharmaceuticals develops treatments that it either licenses to other drugmakers or brings to market itself. Most revenue has come from collaborations and licenses, rather than medicine sales, and depends on a small number of partners. Novo Nordisk, a major revenue source, holds worldwide rights to LX9851, a preclinical candidate for obesity and related cardiometabolic disorders. Viatris holds rights to develop and sell sotagliflozin outside the United States and Europe. These arrangements bring upfront payments, with further revenue dependent on development milestones and royalties from partners’ product sales.
Lexicon also sells INPEFA, its approved sotagliflozin medicine, in the United States through wholesalers and selected retail pharmacies. It is approved to reduce cardiovascular death and heart-failure-related hospitalizations and urgent visits in specified adults with heart failure or with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. Product sales are the smaller revenue stream and depend heavily on insurance coverage and reimbursement. Lexicon has scaled back INPEFA commercial operations and no longer maintains a substantial sales infrastructure.
Its own development work includes sotagliflozin for hypertrophic cardiomyopathy and pilavapadin for neuropathic pain. New uses and drug candidates require regulatory approval before commercialization. Advancing these programs depends on clinical results, partner commitments and funding; Lexicon lacks sufficient capital to take pilavapadin into late-stage development without a collaboration or another arrangement.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Lexicon's licensing revenue depends heavily on Novo Nordisk, which pays for worldwide rights to develop, manufacture and sell its obesity candidate LX9851. The $45 million upfront payment supplied most of Lexicon's 2025 revenue; LX9851 milestone progress brought another $10 million in February 2026.
Lexicon's licensing income depends on Viatris advancing sotagliflozin in all markets outside the United States and Europe, where Viatris paid for the rights to develop and sell the drug. After the $25 million upfront payment in 2024, watch development milestones and commercialization progress in those markets for future licensing revenue.
Cytokinetics sells MYQORZO to treat hypertrophic cardiomyopathy (HCM), competing for the patients and cardiologists Lexicon targets with its Phase 3 sotagliflozin program. Watch MYQORZO's Phase 3 results in non-obstructive HCM, a patient group also included in Lexicon's trial.
Edgewise Therapeutics is developing EDG-7500 for HCM patient groups that overlap with Lexicon's sotagliflozin program. Watch whether EDG-7500's clinical results support Edgewise's claim that it could offer a distinct treatment profile across HCM types; that benefit is not yet established.
Bristol Myers Squibb sells Camzyos for HCM, competing with Lexicon's sotagliflozin development program, and also stands to receive a payment from Lexicon under their drug-discovery alliance. Lexicon must pay it $5 million when the first patient receives a dose in a Phase 3 pilavapadin trial.
Braveheart Bio is developing BHB-1893 for obstructive HCM, competing with Lexicon's Phase 3 sotagliflozin program for the same patient group. Watch its planned 2026 global Phase 3 trial: BHB-1893 is Braveheart's sole drug candidate.
vTv Therapeutics and Lexicon both seek approval for drugs used alongside insulin in type 1 diabetes: cadisegliatin and sotagliflozin, respectively. Watch cadisegliatin's Phase 3 results, while Lexicon continues pursuing approval after the FDA declined sotagliflozin for this use in late 2024.
Fed Interest Rate Decision
Lexicon’s Fed-linked borrowing costs affect how much cash it pays in interest on its floating-rate Oxford Term Loans.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift interest costs on Lexicon’s floating-rate loans, leaving less cash for research and development and commercialization.
If it comes in below expectations
Lower rates can reduce interest costs on Lexicon’s floating-rate loans, leaving more cash for research and development and commercialization.
Cytokinetics Inc. earningsCYTK
Cytokinetics' report can show MYQORZO sales and progress in non-obstructive hypertrophic cardiomyopathy, a patient market where it competes with Lexicon's sotagliflozin program.
Read any MYQORZO sales or adoption update alongside progress in the Phase 3 program for non-obstructive HCM. Better uptake with encouraging trial progress would make Cytokinetics a more substantial competitor for Lexicon's target patients; weak uptake or a setback would mean less evidence of that pressure, but would not establish that Lexicon's sotagliflozin works.
Novo-Nordisk A/S earningsNVO
If Novo Nordisk's report updates LX9851, it can show whether the licensed program may bring Lexicon further milestone revenue.
Look for any update on LX9851's development and compare it with the license revenue or milestone payments Lexicon has recognized. Progress that triggers another milestone would add a source of collaboration revenue; a delay or setback would weaken that prospect. No mention in the report would not prove the program has stalled.
Lexicon Pharmaceuticals, Inc. earningsThis company
Lexicon earns revenue from both licensing deals and INPEFA sales, and this report will show whether drug sales and earned collaboration milestones are supporting its ongoing operating costs.
Read INPEFA net product revenue alongside collaboration revenue, then compare both with research and selling, general and administrative expenses and cash use. Rising product sales or earned milestones with costs and cash use under control would show Lexicon relying less on one-time license payments to fund its plans; weak revenue with continued cash use would make financing or new deals more important, though revenue alone cannot show whether development will succeed.
Viatris Inc. earningsVTRS
If Viatris reports on sotagliflozin in markets outside the United States and Europe, its report can show whether that license may bring Lexicon further revenue.
Look for any disclosure on sotagliflozin development, commercialization, or milestones, then compare it with the license revenue Lexicon has recognized from collaborations. A clear advance or milestone would point to a possible additional revenue source; a setback would weaken that prospect. If Viatris gives no product-specific detail, its overall results cannot stand in for evidence about this drug.
vTv Therapeutics Inc. earningsVTVT
If vTv Therapeutics updates its Phase 3 results for an insulin-adjunct drug, its report can show whether another type 1 diabetes treatment is advancing in Lexicon's target indication.
Look at cadisegliatin's Phase 3 results and any next regulatory step. Results that support the drug and allow the program to advance would show a competitor progressing in the same type 1 diabetes setting; poor results or a setback would weaken that evidence. Neither outcome replaces the separate safety evidence Lexicon needs to support a resubmission for sotagliflozin.
